Skip to main content
. 2016 Oct 9;7(43):69358–69370. doi: 10.18632/oncotarget.12541

Figure 4. The influence of TMPS pre-treatment (10.0 μM; 100.0 μM; 1000.0 μM) on MRS 2690-induced (1.0 μM; 10.0 μM) β-HEX release from RBL-2H3 cells.

Figure 4

Mast cells were sensitized for 24 h with DNP-specific IgE antibody (0,5 μg/ml)and pre-incubated with TMPS for 10 minutes before the application of MRS 2690 serving as the control agonist. The spontaneous release (9.5%) was subtracted from the final data. Data represent the means ± SD from at least three independent experiments; * p < 0.05, *** p < 0.001 when compared to DNP-HSA or ≠p < 0.05, ≠≠ p < 0.01 when compared to MRS 2690.